FASTTRACK Cost-effectiveness of cardiac resynchronization therapy: Results from the CARE-HF trial

European Heart Journal

Volumn 26, Issue 24, 2005, Pages 2681-2688

  Calvert, Melanie J ^a   Freemantle, Nick ^a   Yao, Guiqing ^a   Cleland, John G F ^b   Billingham, Lucinda ^a   Daubert, Jean Claude ^c   Bryan, Stirling ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cardiac resynchronization therapy; CARE HF; Cost effectiveness; Quality adjusted life year

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HOSPITAL CHARGE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL; TREATMENT OUTCOME; ADOLESCENT; ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; CARDIAC PACING, ARTIFICIAL; COST-BENEFIT ANALYSIS; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 28544433628     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi662     Document Type: Article

References (46)

1. http://www.americanheart.org/presenter.jhtml?identifier=1486 (12 May 2005).
2. http://www.escardio.org/knowledge/ehs/survey/Heart_Failure_II.htm (12 May 2005).
3. Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail 2005;7:423-428.
4. Khand AU, Gemmell I, Rankin AC, Cleland JGF. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J 2001;22:153-164.
5. Xiao HB, Brecker SJD, Gibson DG. Differing effects of right ventricular pacing and left bundle branch block on left ventricular function. Br Heart J 1993;69:166-173.
6. Daubert J, Cazeau S, Leclerc C. Do we have reasons to be enthusiastic about pacing to treated advanced heart failure? Eur J Heart Fail 1999;1:289-292.
7. Auricchio A, Klein H, Spinelli F. Pacing for heart failure: selection of patients, techniques and benefits. Eur J Heart Fail 1999;1:275-280.
8. Rogers JG, Cain ME. Electromechanical associations. N Engl J Med 2004;350:2193-2195.
9. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-880.
10. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289:2685-2694.
11. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-1853.
12. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, Yong PG. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003;42:1454-1459.
13. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
14. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, Kass DA, Powe NR. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003;289:730-740.
15. McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, Klassen T, Abraham W. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004;141:381-390
16. (Erratum, Ann Intern Med 2005;142:311).
17. Calvert M, Freemantle N, Cleland JGF. Cardiac resynchronization therapy in heart failure. Ann Intern Med 2005;142:305a.
18. Nichol G, Kaul P, Huszti E, Bridges JFP. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004;141:343-351.
19. Banz K. Cardiac resynchronization therapy (CRT) in heart failure: a model to assess the economic value of this new medical technology. Value Health 2005;8;128-139.
20. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
21. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L; CARE-HF study Steering Committee and Investigators. The CARE-HF study (CArdiac REsynchronization in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:481-489.
22. Akaike H. A new look at statistical model identification. IEEE Trans Automat Contr 1974;19:716-723.
23. Brooks R, de Charro F. EuroQol: the current state of play. Health Policy 1996;37:53-72.
24. Euroqol Group. EQ-5D A Measure of Health-Related Quality of Life Developed by the Euroqol Group. User Guide. www.euroqol.org (2001).
25. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
26. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;Oct/Nov:198-209.
27. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart questionnaire: reliability and validity during a randomized, double blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-1025.
28. McCulloch CE, Searle SR. Generalized, Linear, and Mixed Models. New York: John Wiley; 2001.
29. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
30. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.
31. Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004;8(40):iii-iv, xv-xvi, 1-141.
32. Curtis L, Netten A. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent; 2004.
33. Department of Health. Reference Costs 2004. http://www.dh.gov.uk/ assetRoot/04/10/55/53/04105553.xls (6 May 2005).
34. British National Formulary. http://www.bnf.org/bnf/ (14 March 2005).
35. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford University Press; 1997.
36. Medtronic Inc. Insync III 8042 Implant Manual. 2001.
37. ICH E9 Expert Working Group. ICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials (ICH E9). Stat Med 1999;18:1905-1942.
38. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-1200.
39. HM Treasury Green Book. http://greenbook.treasury.gov.uk/ (6 May 2004).
40. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-227.
41. http://www.euroqol.org/web/users/valuation_b.php (10 May 2005).
42. Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001;21:7-16.
43. Johnson JA, Luo N, Shaw JW, Kind P, Coons SJ. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care 2005;43:221-228.
44. Greiner W, Claes C, Busschbach JJV, Graf von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005;6:124-130.
45. http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do? itemId=1097076282648&lang=en_US (12 May 2005).
46. http://www.guidant.com/news/400/web_release/nr_000435.shtml (12 May 2005).